Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tacrolimus is More Effective than Pimecrolimus For Atopic Dermatitis

02.08.2004


Data presented here today at the Academy 2004 meeting of the American Academy of Dermatology demonstrate that tacrolimus ointment is more effective than pimecrolimus cream in the treatment of adult and pediatric patients with atopic dermatitis (AD).



Overall results also revealed that in the same patient populations, both treatments have similar safety profiles including no statistical difference with regard to burning and stinging. These findings were presented by Alan Fleischer, M.D., study investigator, professor, chair and director of the General Dermatology Clinic, Wake Forest University Baptist Medical Center. They support preliminary data presented by Fleischer in February at the academy’s annual meeting.

“This study is the first, large, well-designed comparative trial to examine tacrolimus ointment and pimecrolimus cream in the same patient populations, including age, disease severity, length of treatment, efficacy endpoints and adverse events,” said Fleischer. “In this study, tacrolimus ointment seemed to work better for all severities of atopic dermatitis than pimecrolimus, including mild sufferers and particularly in severe patients.”


The six-week, randomized, investigator-blinded study evaluated 1,056 patients, including children as young as 2, with mild to severe AD. Treatment success was defined by the Investigator’s Global Atopic Dermatitis Assessment (IGADA) as “clear” or “almost clear.”

The first arm evaluated adult patients with mild to very severe AD. At six weeks, 46 percent of 210 patients treated with tacrolimus ointment 0.1 percent were rated as “clear” or “almost clear” compared with 27 percent of 203 patients receiving pimecrolimus cream 1 percent. The second arm evaluated tacrolimus ointment 0.1 percent or pimecrolimus cream 1 percent in pediatric patients ages 2 to 15 with moderate to very severe AD. Of 112 children treated with tacrolimus ointment, 32 percent achieved treatment success compared with 18 percent of children treated with pimecrolimus cream. The third arm evaluated tacrolimus ointment 0.03 percent or pimecrolimus cream 1 percent in pediatric patients with mild AD. Forty-seven percent of 208 children treated with tacrolimus ointment achieved treatment success compared with 41 percent of 217 patients using pimecrolimus cream.

“This study revealed that tacrolimus and pimecrolimus patients had a comparable tolerability including burning and stinging,” said Fleischer. “Patients treated with tacrolimus ointment for all severities of atopic dermatitis experienced a greater and more rapid reduction in itching symptoms, which is key to improving the quality of life for these patients.”

Efficacy of the two treatments was comprehensively measured at day 1 and weeks 1, 3 and 6, using the physician-rated Body Surface Area (BSA) assessment, and the six-point IGADA, which evaluated the major symptoms of AD. An Eczema Area and Severity Index score also was calculated and a patient’s evaluation of itch was recorded at each visit.

“This study supports existing data that show that tacrolimus and pimecrolimus have the same safety profile and comparable tolerability,” said Fleischer. “Tacrolimus works more rapidly at the skin’s surface than pimecrolimus, yet existing data indicate that neither medication showed a trend toward higher blood accumulation over time deeming them equally safe.”

The study was funded by Fujisawa Healthcare Inc., which makes tacrolimus ointment. It is available by prescription in two concentrations for adults, 0.03 percent and 0.1 percent. For children ages 2 to 15, the 0.03 percent concentration is indicated.

Topical immunomodulators, a nonsteroidal class of topical agents that are safer than corticosteroids, are the first new class of prescription drugs to be developed in more than 40 years for the treatment of AD. The FDA approved tacrolimus ointment, the steroid-free alternative, in December 2000 for short-term and intermittent long-term therapy to treat the signs and symptoms of moderate to severe AD in children and adults. Pimecrolimus cream 1 percent was approved in December 2001 for short-term and intermittent long-term treatment of mild to moderate AD in patients ages 2 and older.

| newswise
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>